Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Setting the Stage for 2018: How the Changes in the American Joint Committee on Cancer/Union for International Cancer Control <i>Cancer Staging Manual</i> Eighth Edition Impact Radiologists.

AJNR. American journal of neuroradiology·2017
Same author

Advanced dual-energy CT applications for the evaluation of the soft tissues of the neck.

Clinical radiology·2017
Same author

Feasibility analysis of the parametric response map as an early predictor of treatment efficacy in head and neck cancer.

AJNR. American journal of neuroradiology·2015
Same author

CT perfusion can predict overexpression of CXCL8 (interleukin-8) in head and neck squamous cell carcinoma.

AJNR. American journal of neuroradiology·2013
Same author

Human papillomavirus, p16, and epidermal growth factor receptor biomarkers and CT perfusion values in head and neck squamous cell carcinoma.

AJNR. American journal of neuroradiology·2013
Same author

Neuroradiology back to the future: head and neck imaging.

AJNR. American journal of neuroradiology·2012
Same journal

CT Evaluation of Osseous Trauma at the Craniocervical Junction: A Pattern-Based Overview.

AJNR. American journal of neuroradiology·2026
Same journal

Comprehensive Structural MRI Phenotyping in <i>Oligophrenin 1-</i>Related Disorder Reveals Characteristic Brain Malformations.

AJNR. American journal of neuroradiology·2026
Same journal

ASNR-ESNR White Paper on Sustainability in Neuroradiology.

AJNR. American journal of neuroradiology·2026
Same journal

Intracranial Atherosclerotic Disease Distribution Across Circle of Willis Segments: Insights from CREST-H.

AJNR. American journal of neuroradiology·2026
Same journal

Regional Cerebral Blood Flow Patterns on ASL in Subacute Sclerosing Panencephalitis: Quantitative Analysis and Clinical Correlation.

AJNR. American journal of neuroradiology·2026
Same journal

Improved Diagnostic Certainty of Photon-Counting CT Myelography Compared with Energy-Integrating CT for CSF-Venous Fistulas in Spontaneous Intracranial Hypotension.

AJNR. American journal of neuroradiology·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Temozolomide (Temodar).

J R Wesolowski1, P Rajdev, S K Mukherji

  • 1University of Michigan Medical Center, Ann Arbor, MI, USA. jefwesol@med.umich.edu

AJNR. American Journal of Neuroradiology
|June 12, 2010
PubMed
Summary
This summary is machine-generated.

Temozolomide is an oral chemotherapy drug used for brain tumors like anaplastic astrocytoma and glioblastoma multiforme. This paper explores its mechanism of action and clinical applications.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Temozolomide is an oral alkylating agent.
  • It is frequently used in treating anaplastic astrocytoma and glioblastoma multiforme.

Purpose of the Study:

  • To present the mechanism of action of temozolomide.
  • To outline the clinical role of this chemotherapeutic drug.

Main Methods:

  • Literature review of temozolomide's properties and uses.

Main Results:

  • Temozolomide functions as an alkylating agent.
  • Its clinical utility is established in specific brain tumor treatments.

Conclusions:

  • Temozolomide is a key chemotherapeutic agent for certain brain cancers.
  • Understanding its action and role is crucial for effective treatment strategies.